ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase I/II Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

ALX Oncology Holdings, Inc. announced the first patient has been dosed in the Phase I/II ASPEN-05 study evaluating the combination of evorpacept with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia.